Catumaxomab for Treatment of Peritoneal Carcinomatosis in Patients With Gastric Adenocarcinomas — CatuNeo  

Gastric Adenocarcinoma With Peritoneal Carcinomatosis Clinical Trial

Official title: Explorative Trial to Investigate Catumaxomab (Anti-EpCAM x Anti-CD3) for Treatment of Peritoneal Carcinomatosis in Patients With Gastric Adenocarcinomas Prior to Gastrectomy

Status Completed

Clinical Trial Summary

The purpose of this study is to determine the efficacy of catumaxomab by determination of the rate of macroscopic complete remissions of peritoneal carcinomatosis after treatment with one cycle (four doses) of catumaxomab followed by six cycles of routine neoadjuvant chemotherapy.

Clinical Trial Description

n/a

Related Conditions & MeSH terms

• Adenocarcinoma
• Carcinoma
• Gastric Adenocarcinoma With Peritoneal Carcinomatosis
• Siewert Type II Adenocarcinoma of Esophagogastric Junction With Peritoneal Carcinomatosis
• Siewert Type III Adenocarcinoma of Esophagogastric Junction With Peritoneal Carcinomatosis

• NCT number: NCT01504256
• Study type: Interventional
• Source: AIO-Studien-gGmbH
• Status: Completed
• Phase: Phase 2
• Start date: October 2011
• Completion date: July 2017